All Outputs (3)

Detection of Label-Free Drugs within Brain Tissue Using Orbitrap Secondary Ion Mass Spectrometry as a Complement to Neuro-Oncological Drug Delivery (2022)
Journal Article
McCrorie, P., Rowlinson, J., Scurr, D. J., Marlow, M., & Rahman, R. (2022). Detection of Label-Free Drugs within Brain Tissue Using Orbitrap Secondary Ion Mass Spectrometry as a Complement to Neuro-Oncological Drug Delivery. Pharmaceutics, 14(3), Article 571. https://doi.org/10.3390/pharmaceutics14030571

Historically, pre-clinical neuro-oncological drug delivery studies have exhaustively relied upon overall animal survival as an exclusive measure of efficacy. However, with no adopted methodology to both image and quantitate brain parenchyma penetrati... Read More about Detection of Label-Free Drugs within Brain Tissue Using Orbitrap Secondary Ion Mass Spectrometry as a Complement to Neuro-Oncological Drug Delivery.

Intratumour heterogeneity in microRNAs expression regulates glioblastoma metabolism (2021)
Journal Article
Alfardus, H., de los Angeles Estevez Cebrero, M., Rowlinson, J., Lourdusamy, A., Abdelrazig, S., Ortori, C., …Smith, S. (2021). Intratumour heterogeneity in microRNAs expression regulates glioblastoma metabolism. Scientific Reports, 11(1), Article 15908. https://doi.org/10.1038/s41598-021-95289-9

While specific microRNA (miRNA) signatures have been identified in glioblastoma (GBM), the intratumour heterogeneity in miRNA expression has not yet been characterised. In this study, we reveal significant alterations in miRNA expression across three... Read More about Intratumour heterogeneity in microRNAs expression regulates glioblastoma metabolism.

Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential (2020)
Journal Article
Smith, S. J., Rowlinson, J., Estevez-Cebrero, M., Onion, D., Ritchie, A., Clarke, P., …Rahman, R. (2020). Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential. Neuro-Oncology Advances, 2(1), Article vdaa087. https://doi.org/10.1093/noajnl/vdaa087

Background Glioblastoma (GBM) is a highly aggressive brain tumor with rapid subclonal diversification, harboring molecular abnormalities that vary temporo-spatially, a contributor to therapy resistance. Fluorescence guided neurosurgical resection ut... Read More about Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential.